<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715321</url>
  </required_header>
  <id_info>
    <org_study_id>SCT-01</org_study_id>
    <nct_id>NCT04715321</nct_id>
  </id_info>
  <brief_title>CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma Study</brief_title>
  <official_title>Computed Tomography Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Distinct vascular patterns (ECTC or Non-ECTC) of tumors plays an important role in tumor&#xD;
      migration, metastasis and drug resistant in hepatocellular carcinoma (HCC). However, there is&#xD;
      no non-invasive method to predict vascular pattern in clinical. In the present study, we&#xD;
      prospectively assess CT perfusion parameters for evaluation of the vascular pattern in HCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive performance of CT perfusion</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome of our study is to evaluate the sensitivity and specifity of CT perfusion in predicting vascular pattern of HCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>OS is the length of time from the date of randomization until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Disease-free survival is calculated from the date of surgery to tumor recurrence or death from any cause (or the date of the last follow-up if the patient was alive)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>HCC patients enrolled in our study underwent a perfusion CT examination before surgery . We used CT perfusion parameters to predict the vascular pattern of tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>HCC patients who would undergo a perfusion CT examination before surgery will be enrolled in our study from January 15, 2021. We use CT perfusion parameters to predict the vascular pattern of tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT perfusion examination</intervention_name>
    <description>CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.</description>
    <arm_group_label>Training cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HCC patients with tumor size of less than 5 cm who would receive liver resection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age over than 18 years old&#xD;
&#xD;
          2. tumor size of less than 5 cm&#xD;
&#xD;
          3. Child-Pugh A class liver function&#xD;
&#xD;
          4. an Eastern Cooperative Oncology Group performance status of 0&#xD;
&#xD;
          5. no previous treatment for HCC&#xD;
&#xD;
          6. pathological diagnosis of hepatocellular carcinoma&#xD;
&#xD;
          7. adequate organ function (white blood cell count ≥3.0 × 109/L, absolute neutrophil&#xD;
             count ≥1.5 × 109/L, platelet count ≥75 × 109/L, aspartate transaminase and alanine&#xD;
             transaminase≤5 × upper limit of the normal, creatinine clearance rate of ≤1.5 × upper&#xD;
             limit of the normal, and left ventricular ejection ≥45%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received antitumor therapy before recurrence, including radiotherapy,&#xD;
             transarterial chemoembolization, tyrosine kinase inhibitor, and immune checkpoint&#xD;
             inhibitor&#xD;
&#xD;
          2. a known medical history of HIV infection&#xD;
&#xD;
          3. pregnancy or breastfeeding&#xD;
&#xD;
          4. portal vein tumor thrombosis or hepatic vein thrombosis detected by any routine&#xD;
             imaging modality, including ultrasonography, dynamic contrast CT and MRI&#xD;
&#xD;
          5. any evidence of tumor metastasis or prior recurrence&#xD;
&#xD;
          6. hepatic decompensation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, MD</last_name>
      <phone>8620-87343115</phone>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>CT perfusion parameters</keyword>
  <keyword>vascular pattern</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

